GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

PF-04950615

Company
Pfizer
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00991159

    A Study To Access The Safety And Tolerability Of RN316 (PF-04950615) When Administered To Healthy Adult Subjects

    Not yet reported Pfizer 48 participants Est. completion 2010-05 2 sites
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01163851

    Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

    Not yet reported Pfizer 25 participants Est. completion 2011-04 5 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01243151

    Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia

    Not yet reported Pfizer 68 participants Est. completion 2011-10 9 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01342211

    A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

    Not yet reported Pfizer 93 participants Est. completion 2012-06 44 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01350141

    A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

    Not yet reported Pfizer 46 participants Est. completion 2012-06 35 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemia
    View official trial listing →
  • Completed NCT NCT01435382

    A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia

    Not yet reported Pfizer 49 participants Est. completion 2012-04 7 sites Stand-alone
    Other conditions: Hypercholesterolemia, Dyslipidemias, Hyperlipidemias, Lipid Metabolism Disorders, Metabolic Diseases
    View official trial listing →
  • Completed NCT NCT01592240

    Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin

    Not yet reported Pfizer 354 participants Est. completion 2013-05 74 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT01720537

    A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects

    Not yet reported Pfizer 133 participants Est. completion 2013-10 7 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT01968954

    Randomized Clinical Trial Of Bococizumab (PF-04950615; RN316) In Subjects With Hyperlipidemia Or Mixed Dyslipidemia At Risk Of Cardiovascular Events

    Not yet reported Pfizer 711 participants Est. completion 2016-04 103 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT01968967

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

    Not yet reported Pfizer 2139 participants Est. completion 2017-07-10 249 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT01968980

    A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia

    Not yet reported Pfizer 370 participants Est. completion 2016-04-15 88 sites Stand-alone
    Other conditions: Heterozygous Familial Hypercholesterolemia
    View official trial listing →
  • Terminated NCT NCT01975376

    The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

    Not yet reported Pfizer 16784 participants Est. completion 2017-03-22 1745 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Terminated NCT NCT01975389

    The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

    Not yet reported Pfizer 10564 participants Est. completion 2017-04-03 1595 sites Stand-alone
    Cardiovascular disease
    View official trial listing →
  • Completed NCT NCT02043301

    Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm

    Not yet reported Pfizer 75 participants Est. completion 2014-11 6 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT02055976

    Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects

    Not yet reported Pfizer 218 participants Est. completion 2015-01 9 sites Stand-alone
    Other conditions: Hypercholesterolemia
    View official trial listing →
  • Completed NCT NCT02100514

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

    Not yet reported Pfizer 746 participants Est. completion 2017-07-10 223 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Completed NCT NCT02135029

    Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

    Not yet reported Pfizer 184 participants Est. completion 2015-11 40 sites Stand-alone
    Other conditions: Hyperlipidemia
    View official trial listing →
  • Terminated NCT NCT02524106

    Bococizumab HIV Evaluation (B-HIVE) Study

    Not yet reported University of California, San Francisco 11 participants Est. completion 2017-11 3 sites Stand-alone
    Cardiovascular disease Other conditions: Dyslipidemia
    View official trial listing →
  • Terminated NCT NCT02667223

    Pharmacokinetic and Pharmacodynamic Study of Bococizumab Alone and When Combined With Recombinant Human Hyaluronidase

    Not yet reported Pfizer 60 participants Est. completion 2016-07 1 site
    Other conditions: Healthy, Hypercholesterolemia
    View official trial listing →
  • Withdrawn NCT NCT02947334

    Efficacy And Safety Of Bococizumab For Lipid Lowering In Asian Hypercholesterolemia Subjects

    Not yet reported Pfizer Est. completion 2019-05-03 1 site
    Other conditions: Primary Hyperlipidemia or Mixed Dyslipidemia
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: PF-04950615, PF-04950615 (RN316)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.